Miist Therapeutics applies a physics-based approach to develop inhaled therapies that are faster acting and more effective than today's standard of care. The company's core technology is an inhaler that uses ultrasonic vibration to generate and deliver 2-micron aqueous drug particles to the peripheral lung, where they are instantly absorbed into the bloodstream. Using this novel approach, Miist is developing new inhaled therapies that will deliver instant relief for some of our most common and debilitating conditions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/05/25 | $7,000,000 | Seed |
1517 Fund California Innovation Fund Entrepreneur First Freeflow Ventures Refactor Capital | undisclosed |
